Syndax Pharmaceuticals (NASDAQ:SNDX) is now trading -13.16% off 52-week high price. On the other end, the stock has been noted 236.64% away from the low price over the last 52-weeks. The stock changed -1.91% to recent value of $18.01. The stock transacted 486047 shares during most recent day however it has an average volume of 587.90K shares. The company has 29.97M of outstanding shares and 27.35M shares were floated in the market.

On May 07, 2020, Syndax Pharmaceuticals (NASDAQ:SNDX) a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, released its financial results for the first quarter ended March 31, 2020. In addition, the Company provided a clinical and business update.

During the first quarter, we generated significant momentum that we believe will take us through what we expect will be a transformational year for Syndax, with key data readouts expected across the entirety of our portfolio, said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. We continue to anticipate the final overall survival readout from E2112, our Phase 3 registration trial of entinostat plus exemestane in HR+, HER2- breast cancer later this quarter, with a potential regulatory filing for entinostat in HR+ breast cancer by year end. Supported by the compelling overall survival benefit observed in the Phase 2b ENCORE 301 trial, we believe the combination of entinostat and exemestane has strong potential to serve as a much-needed option in a setting for which existing therapies are inadequate. While we await this final readout, we remain focused on preparations to establish ourselves as a fully integrated oncology company, with a potential launch expected in 2021.

Dr. Morrison added, Beyond entinostat, we were pleased to recently announce initial Phase 1 data from the AUGMENT-101 trial of SNDX-5613, our oral menin inhibitor, in adults with relapsed/refractory acute leukemias. These data provide the first clinical evidence that inhibition of the menin-MLL1 interaction can induce response in patients with MLL-r acute leukemias. We believe that SNDX-5613 has great potential to serve as an effective intervention for both MLL-r acute leukemias and NPM1 mutant AML, and we look forward to presenting additional data from this trial in the fourth quarter of this year. With a strong balance sheet, which includes proceeds from our recent follow-on offering, we believe we are well positioned to execute on upcoming milestones.

Its earnings per share (EPS) expected to touch remained 36.90% for this year.

According to the most recent quarter its current ratio was 3.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of 33.40% from the mean of 20 days, 58.98% from mean of 50 days SMA and performed 98.40% from mean of 200 days price. Company’s performance for the week was 0.06%, 96.83% for month and YTD performance remained 105.13%.